Veille documentaire MTPH

Médecine du travail du personnel hospitalier

Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons

Auteur     James W. Keck
Auteur     Lisa R. Bulkow
Auteur     Gregory A. Raczniak
Auteur     Susan E. Negus
Auteur     Carolyn L. Zanis
Auteur     Michael G. Bruce
Auteur     Philip R. Spradling
Auteur     Eyasu H. Teshale
Auteur     Brian J. McMahon
Volume     21
Numéro     9
Pages     1339-1342
Publication     Clinical and vaccine immunology: CVI
ISSN     1556-679X
Date     Sep 2014
Résumé     Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml.

Export bibliographique

Chercher cette référence sur : Google Scholar, Worldcat

doi:10.1128/CVI.00263-14

Laisser une réponse

Vous devez etre connectez Pour poster un commentaire